A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal by Rothwell, J.C. et al.
This is a repository copy of A study of target effect sizes in randomised controlled trials 
published in the Health Technology Assessment journal.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/137234/
Version: Published Version
Article:
Rothwell, J.C. orcid.org/0000-0001-6275-3807, Julious, S.A. and Cooper, C.L. (2018) A 
study of target effect sizes in randomised controlled trials published in the Health 
Technology Assessment journal. Trials, 19. 544. 
https://doi.org/10.1186/s13063-018-2886-y
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH Open Access
A study of target effect sizes in randomised
controlled trials published in the Health
Technology Assessment journal
Joanne C. Rothwell1,3* , Steven A. Julious1 and Cindy L. Cooper2
Abstract
Background: When designing a randomised controlled trial (RCT), an important consideration is the sample size
required. This is calculated from several components; one of which is the target difference. This study aims to
review the currently reported methods of elicitation of the target difference as well as to quantify the target
differences used in Health Technology Assessment (HTA)-funded trials.
Methods: Trials were identified from the National Institute of Health Research Health Technology Assessment journal. A
total of 177 RCTs published between 2006 and 2016 were assessed for eligibility. Eligibility was established by the design
of the trial and the quality of data available. The trial designs were parallel-group, superiority RCTs with a continuous
primary endpoint. Data were extracted and the standardised anticipated and observed effect size estimates were
calculated. Exclusion criteria was based on trials not providing enough detail in the sample size calculation and
results, and trials not being of parallel-group, superiority design.
Results: A total of 107 RCTs were included in the study from 102 reports. The most commonly reported method
for effect size derivation was a review of evidence and use of previous research (52.3%). This was common across
all clinical areas. The median standardised target effect size was 0.30 (interquartile range: 0.20–0.38), with the median
standardised observed effect size 0.11 (IQR 0.05–0.29). The maximum anticipated and observed effect sizes were 0.76
and 1.18, respectively. Only two trials had anticipated target values above 0.60.
Conclusion: The most commonly reported method of elicitation of the target effect size is previous published research.
The average target effect size was 0.3.
A clear distinction between the target difference and the minimum clinically important difference is recommended when
designing a trial. Transparent explanation of target difference elicitation is advised, with multiple methods including a
review of evidence and opinion-seeking advised as the more optimal methods for effect size quantification.
Keywords: Randomised controlled trial, Target difference, Effect size, HTA, Health technology assessment
Background
The major funder of research into clinical interven-
tions in the United Kingdom (UK) is the National In-
stitute of Health Research (NIHR), and the biggest
programme within that is the Health Technology As-
sessment Programme (HTA). The HTA funds commis-
sioned and researcher-led health-related research
including randomised controlled trials (RCTs) of clin-
ical interventions in the UK [1, 2].
One of the conditions of funding from the HTA is that
all studies must write a HTA report to be published in
the Healthy Technology Assessment (HTA) journal. Many
trials which are funded by the HTA are also published in
journals such as the Lancet, the British Medical Journal
and the New England Journal of Medicine. However, the
HTA publishes all reports for trials it funds, irrespective
of the statistical significance achieved, and these reports
have greater detail than journal articles can include.
Therefore, journals published in the HTA journal are
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suitable for review as they are published in detail, are of
high scientific standard and are published regardless of
the positive or negative nature of the results.
A key component when designing a clinical trial is the
sample size justification. If there are too few participants
then the trial may not result in statistical significance even
if there is a true effect [3]. Conversely, having too many
participants could result in unethical practice; for ex-
ample, randomising unnecessary numbers of participants
to a treatment which could may be shown to be inferior
or harmful earlier and delaying the results of the study [3].
The most sensitive part of the traditional sample size
calculation is the anticipated difference or effect size be-
tween treatments. This difference can be categorised as
either a clinically meaningful difference or a target dif-
ference. A clinically meaningful difference is the value
above which you would accept that one treatment is
clinically superior to another. However, it may not al-
ways be desirable to use a clinically meaningful differ-
ence. It could be that we need to demonstrate a
difference greater than the minimum clinically meaning-
ful difference to influence medical practice or policy.
The target difference may then be set higher than the
minimum clinically meaningful difference. Throughout
this paper we will use target difference when talking
about the effect size.
The elicitation of this target difference is a widely dis-
cussed issue, with a large review being performed in
2014 by Cook et al. which showed that a variety of
methods are used in establishing a target effect size [4,
5]. This study draws from the findings of the DELTA
project, a Medical Research Council (MRC)-funded
study which resulted in the publication by Cook et al.,
and has been performed as part of the DELTA2 project,
also funded by the Medical Research Council (MRC).
The purpose of the DELTA2 project is to formulate guid-
ance on choosing the target difference for RCTs, aiming
to assist trialists in the design of trials. This study uses the
definitions of target difference elicitation methods devel-
oped by the original DELTA project in the review.
This study aims to assess the currently reported
methods of elicitation of the target difference as well as
quantify the target differences used in HTA-funded trials.
Methods
Trial identification
A review of RCTs published in the HTA journal between
2006 and 2016 was performed. This time frame was chosen
primarily because based on an initial scoping study to as-
sess if there were sufficient eligible reports, as well as being
recent and manageable for the author in the time frame.
The use of the HTA journal as the data source for this
study means that both statistically significant and
non-significant trials are included, since the journal reports
trials irrespective of their resulting statistical significance.
This ensures that reporting bias is not thought to be an im-
portant problem in this study. Without the implications of
reporting bias, and the high level of detail that is included
in HTA journal reports, the choice of the HTA journal al-
lows greater understanding and transparency.
The search criteria consisted of including only RCTs
with a parallel-group design which had the objective to
assess superiority. The reason for this decision was due
to the parallel-group design being the most commonly
undertaken. This was confirmed by an initial scoping of
the HTA report.
The scoping consisted of assessing volumes 19 and 18
for the number of reported RCTs and their designs. The
proportion of reports which were concerned with RCTs
in these volumes were 23.9 and 20.6% for volumes 18
and 19, respectively. Of these RCTs, the percentage of
parallel-group superiority RCTs was 78% for volume 19
and 80% for volume 18.
Further exclusions were trials which did not contain
the enough information for appropriate analyses to be
performed, trials with more than three arms due to the
additional complexities involved in co-primary endpoints
and vaccination trials which also had multiple primary
endpoints. These multiple primary endpoints resulted in
more than one target difference in the various sample
size calculations, making data extraction complex.
Data extraction
Each trial included had a unique identifier the Inter-
national Standard Randomised Controlled Trial Number
(ISRCTN). Data that could not be extracted from the in-
cluded trials were denoted as ‘Missing’.
Data extraction was completed using a series of Microsoft
Excel spreadsheets with a large variety of variables and
free-text boxes for further information if required. A full list
of extracted variables can be seen in the Appendix. The
extraction was carried out by one reviewer over a period of
9 months. All categorical variables were coded prior to
completion of data extraction, with further additions to the
coding if this provided clarity for various design features.
For example, the clinical areas and elicitation methods were
amended during data extraction to provide more informa-
tion, as described in the next section.
Categorisation of variables
In the event of a categorical variable being subjective in
nature, or outside the immediate understanding of the
reviewer, further advice was sought. This occurred for
two variables, the clinical area of the trial and the target
effect size elicitation method.
For the clinical categorisation, data were initially cate-
gorised into 15 clinical areas. At an interim assessment
point, however, a large number of trials fell into the
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‘Other’ category (18.7%). Advice provided by a physician
resulted in a further five clinical categories which were
Renal/Urology, Special Senses (Ear, Nose and Throat
(ENT) and Ophthalmology), Geriatrics, Critical Care,
Emergency Care and Lifestyle. After extraction, categor-
ies which were only assigned to one trial were combined
into an ‘Other’ category to reduce the large number of
categories. The combined categories were Haematology,
Emergency Care and Primary Care.
The category labelling (or describing) the target dif-
ference elicitation methods was handled in a different
manner. This was based on that used by Cook [4].
This used seven broad categories which are the
methods of:
 Anchor
 Distribution
 Health economic
 Opinion-seeking
 Pilot study
 Review of evidence-base method
 Standardised effect size
These methods are described briefly, with further in-
formation found in a publication by Cook et al. [4, 5].
Anchor method
This method starts by establishing the anchor, by calcu-
lating a mean change in ‘score’ for patients who have
expressed that a minimum clinically important differ-
ence or change has occurred in the context of quality-
of-life measures [6, 7]. This change in their quality of life
measure can then be evaluated and used as a clinically
important difference in future trials using the same out-
come measure. It then tries to implement the minimum
clinically important difference (MCID) found in the first
part. This will change depending on the measure being
used.
Another variation of this method is to ‘anchor’ a new
outcome measure to a previously used outcome measure,
when both measures are correlated [8, 9]. An example of
this would be trying to implement a new quality of life
(QoL) measure or subscale, and anchoring it to a generic
QoL questionnaire.
Distribution method
The distribution method uses the imprecision value of the
measurement in question (how reliable is the measure-
ment) and results in the MCID being a value which is lar-
ger than this imprecision value, therefore being likely to
represent a meaningful difference [10]. A common ap-
proach is to use test-retest data for an outcome [4]. This
can help specify the size of the difference due to random
variation in the measurement of the outcome.
Health economic method
This method tries to consider not only the MCID, but
also the cost of the treatment and any other factors
which are deemed to be important when deciding
whether to run a trial. This method aims to establish a
threshold value which is deemed acceptable for the cost
per unit increase in health [11]. It estimates the relative
efficiency of the treatments which can then be compared
directly. This method is not commonly used in practice,
with all 13 papers which used this method to establish
the MCID using hypothetical datasets [4].
Opinion-seeking
This method is more intuitive, based on determining a
value or a range of values for the clinically meaningful
difference. This is established by asking clinicians or ex-
perts in the relevant fields to provide a professional
opinion [4]. These experts could be patients [12, 13], cli-
nicians or a combination [14], for example, with each
providing a different perspective of what they deem
important.
Pilot study
A pilot study is a small version of the trial which is being
planned [15, 16]. Conventionally used to assess the feasi-
bility of the main trial, though information can be col-
lected to aid sample size calculation such as the effect
size and population standard deviation [17, 18]. The ef-
fect size observed in a pilot study can be used as a start-
ing point to help determine the MCID [4]. This method
is commonly used but not often reported [4].
Review of evidence base
This method collects all existing evidence about the
treatment area or population. This allows researchers to
choose an important or realistic difference based on pre-
vious trials and research [19]. The optimum method
used to do this is meta-analysis [4]; however, trialists
should be wary of possible publication bias.
Standardised effect size
The standardised effect size is scale-invariant, which
means that it can be generalised across a variety of clin-
ical areas, it has no units of measurement [4]. For con-
tinuous outcomes, this is calculated by taking the
difference in means and dividing by the pooled standard
deviation [20]. Consider the difference between the two
groups be d, and the pooled population standard devi-
ation be σ, the standardised effect size (δ) can be calcu-
lated as:
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δ ¼ d
σ
:
The size of the standardised effect is used to establish
whether an important difference has occurred, which is
conventionally 0.2 for a small effect, 0.5 for a moderate
effect and 0.8 for a large effect [20]. The benefits of this
method are that it is simple to calculate and allows for
comparisons across different outcomes, trials, popula-
tions and disease areas [4].
These categories were taken from published work and
allowed this study to complement the DELTA2 study cur-
rently being undertaken [21]. This work is being included
in the DELTA2 study, hence the rationale for using the
same categories for target difference elicitation.
Calculating the standardised effect size
For a study with a continuous endpoint that follows a
normal distribution, the standardised effect size is given
by:
δ ¼ d
σ
;
where δ is the standardised effect size, σ is the standard
deviation and d is the target difference.
For a conventional sample size calculation [22] for a
given target sample size, power and significance level
then the standardised target effect size can be calculated
from:
δ¼
ﬃﬃﬃ
2
p
Z1−βþZ1−α=2
 
ﬃﬃﬃ
n
p :
This calculation was used to calculate a scale-independ-
ent value for the target effect size for each study regardless
of the clinical outcome.
The observed effect sizes were standardised using two
methods to ensure similarity. Both these methods use
the standard normal distribution properties of p values
and test statistics.
The first method was based on the provided p value in
the report. To calculate the standardised observed effect
size, the following result was used:
dobserved ¼ Φ−1 p−valueð Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nA
þ 1
nB
r
:
Where nA and nB are the target sample size in each
arm of the trial.
The second method depended on the type of primary
outcome reported; however, this expanded on the first
method. These calculations are given in Table 1.
Statistical analysis
Summary statistics and graphs were used to describe the
data. Expected and observed effect sizes were estimated
using data extracted as discussed in the previous section.
Statistical analyses were conducted using Microsoft
Excel, R and IBM SPSS Version 23.
Results
The database contained information on 107 RCTs from
102 HTA reports. Trials were generally well-reported,
with more information included in trials published after
2010 and after publication of the amended Consolidated
Standards of Reporting Trials (CONSORT) Statement.
Figure 1 gives the flow of trials through the various
stages of the study.
Trial characteristics
Table 2 summarises the characteristics of the included
trials. It can be observed that the number of included
trials increases with more recent volumes. Mental health
was the most common clinical area (N = 18, 14.2%). A
total of 35/107 (32.7%) studies reported statistically sig-
nificant findings for the primary outcome measure.
Elicitation methods
The most commonly reported method of elicitation of
the target effect size is the review of evidence method,
as seen in Table 3. This was reported in 52.3% of reports
Table 1 Calculations used on the extracted data to estimate the standardised observed effect size
Observed effect size type Z-statistic calculation Re-arrangement to get standardised
observed effect size
Mean difference, Difference in proportions,
Regression coefficient, Absolute risk reduction,
Analysis of variance/covariance (ANOVA/ANCOVA)
coefficients
Z ¼ d
SEðdÞ dobserved ¼ Z 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nA
þ 1
nB
q
Odds ratio Z ¼ ln ½OR
SEð ln ½ORÞ dobserved ¼ Z 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nA
þ 1
nB
q
Risk ratio Z ¼ ln ½RR
SEð ln ½RRÞ dobserved ¼ Z 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nA
þ 1
nB
q
Hazard ratio Z ¼ ln ½HR
SEð ln ½HRÞ dobserved ¼ Z 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nA
þ 1
nB
q
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(N = 56), either as the sole method or in combination
with other methods. This elicitation method was the
most common (or equal most common) in all clinical
areas. However, in 19.6% of the reports there was no
mention of the elicitation method used (N = 21).
Standardised effect sizes
Table 4 gives the average target and observed effect sizes
after standardisation, overall and by statistical signifi-
cance. This shows that the median standardised target
effect size was 0.300 (IQR 0.198, 0.377). According to
the standard categories of Cohen [20], (a small effect is
0.2, a moderate effect is 0.5 and a large effect size is 0.8),
this corresponds to a small effect size. The largest stan-
dardised target effect size was 0.760; however, there were
only two trials (1.9%) which used values above 0.600.
The median standardised observed effect size is 0.112
(IQR 0.048, 0.287). The results when split by statistical
significance behave as one would expect. The statistically
significant median for observed effect size is larger than
the target, whilst for the non-significant results it is con-
siderably smaller.
Figure 2 gives the target and observed standardised
effect sizes by whether the study reached statistical
significance. This figure shows that the majority of tri-
als which were not statistically significant had target
effect sizes greater than the observed. This is what one
would expect.
Table 5 gives the standardised expected and observed
effect sizes by the type of primary endpoint used in the
sample size calculation. It can be seen in Table 5 that a
continuous endpoint is the most common type of pri-
mary endpoint (N = 49, 45.6%), closely followed by an
endpoint on proportional scale (N = 41, 38.3%). Trials
using continuous endpoints have higher average standar-
dised observed effect sizes, as well as higher standar-
dised target standardised effect sizes. There are three
trials categorised as ‘Other’, two of which were mean
area under the curve (AUC) across all patients, and one
was an ordinal endpoint. The AUC trials were both
across multiple time points, then the average AUC was
taken as the primary endpoint, with one being a depres-
sion trial and the other being an ulcerative colitis trial.
Figure 3 gives the observed standardised effect sizes
for each clinical area including both the median and
mean. Whilst the median effect size is relatively small,
there are some extreme values. The separation of the
mean and median lines indicate a skew in the data.
Figure 4 gives the target standardised effect sizes for
each clinical area. Both the mean and median are around
0.3, which corresponds to a small effect size in Cohen’s
categories [8].
Table 6 gives the standardised target and observed ef-
fect sizes by clinical area. It can be noted that there is
variation between the size of the effect sizes and clinical
area, with areas such as cardiovascular and critical care
using smaller target effect sizes than mental health, for
Fig. 1 A flow chart displaying the inclusion of trials in the study
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example. It can be observed that, on average, investiga-
tors are anticipating effect sizes of between 0.2 and 0.4
for most clinical areas.
Examples of good practice
A number of reports showed clearly the methods used
to elicit the target effect size and are worthy examples of
good practice. Two examples of good practice have been
included to illustrate how the methods for quantifying
the target difference can be described. They provide
clear and transparent explanations of the journey to
elicit the target effect size for their studies. They also
utilised a variety of methods, including review of evi-
dence and expert opinion, which have been recom-
mended in the DELTA2 guidance for eliciting a realistic
and important difference [23].
TITRe2 trial
The TITRe2 trial (ISRCTN70923932) by Reeves et al.
[24] gives the complex journey that eliciting the target
effect size can be. The trialists’ used a variety of methods
to estimate the target difference and clearly reports them
all for the reader, as well as accounting for the uncer-
tainty in the final estimate. An extract of the sample size
calculation is given below.
The trial was designed to answer superiority
questions. The following steps were taken to calculate
the sample size.
From observational data, we assumed that
approximately 65% of patients would breach the
threshold of 9 g/dl and 20% would breach the 7.5 g/dl
threshold. Therefore, with complete adherence to the
transfusion protocol, we assumed that transfusion
rates should be 100% in the liberal group and ≈ 30%
(0.20/0.65) in the restrictive group.
Table 3 Summary statistics for elicitation method
DELTA elicitation method Frequency %
Anchor 0 0
Distribution 2 1.9
Health economics 1 0.9
Opinion-seeking 10 9.3
Pilot 4 3.7
Review of evidence 49 45.8
Standard effect size (SES) 5 4.7
Mixeda 7 6.5
No mention 21 19.6
Other 8 7.5
a
‘Mixed’ methods included review of evidence
Table 2 Summary characteristics of included trials
Characteristic N (% of total RTCs)
Volume
20 (2016) 20 (18.7)
19 (2015) 19 (17.8)
18 (2014) 12 (11.2)
17 (2013) 11 (10.3)
16 (2012) 8 (7.5)
15 (2011) 6 (5.6)
14 (2010) 8 (7.5)
13 (2009) 10 (9.3)
12 (2008) 2 (1.9)
11 (2007) 3 (2.8)
10 (2006) 8 (7.5)
Clinical area
Cardiovascular 11 (10.3)
Critical Care 2 (1.9)
Dermatology 9 (8.4)
Diabetes 3 (2.8)
Gastrointestinal 9 (8.4)
Geriatrics 2 (1.9)
Immunology 2 (1.9)
Lifestyle 5 (4.7)
Mental Health 18 (14.2%)
Neurology 4 (3.7)
Obstetrics and Gynaecology 2 (1.9)
Oncology 4 (3.7)
Orthopaedics 6 (5.6)
Other 3 (2.8)
Paediatrics 9 (8.4)
Renal/Urology 6 (5.6)
Respiratory 7 (6.5)
Stroke 5 (4.7)
Reached statistical significance?
Yes (p < 0.05) 35/107 (32.7%)
No 72/107 (67.3%)
Final target sample size
Mean 1122
Median 432
Achieved sample size
Mean 1015
Median 404
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In the observational analysis, 63% of patients with a
nadir haematocrit between 22.5 and 27%, and 93% of
patients with a nadir haematocrit below 22.5% were
transfused. Therefore, in combination with the
proportions of patients expected to breach the liberal
and restrictive thresholds, these figures were used to
estimate conservative transfusion rates of 74% for the
liberal group and ≤ 35% for the restrictive group.
These percentages reflected the rates of transfusion
documented in the observational study (Fig. 1) and
assumed non-adherence with the transfusion protocol
of approximately 26% in the liberal group and 5% in
the restrictive group.
The observational frequencies of infectious and
ischaemic events for transfused and non-transfused
patients were adjusted to reflect the estimated
transfusion rates in the two groups (i.e. 74 and ≤
35%), giving event rates for the proposed composite
outcome of 17% in the liberal threshold group and
11% in the restrictive threshold group. A sample size of
1468 was required to detect this risk difference of 6%
Table 4 Standardised effect sizes of trials
Effect size Median (25th, 75th percentiles) Minimum Maximum
Overall
Standardised target 0.300 0.198, 0.377 0.051 0.760
Standardised observed 0.112 0.048, 0.287 < 0.001 1.184
p < 0.05
Standardised target 0.309 0.229, 0.433 0.051 0.643
Standardised observed 0.343 0.230, 0.501 < 0.001 1.184
p > 0.05
Standardised target 0.297 0.183, 0.362 0.070 0.760
Standardised observed 0.061 0.019, 0.155 < 0.001 0.716
Fig. 2 The standardised target and observed effect sizes in the trials, by statistical significance
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Table 5 Standardised effect sizes by type of primary endpoint measure
Primary endpoint
measure
Count Standardised target effect size Standardised observed effect size
Mean Median Mean Median
Overall
Continuous 49 0.375 0.353 0.277 0.219
Proportion 41 0.224 0.198 0.115 0.048
Time to event 10 0.291 0.312 0.147 0.065
Count 4 0.250 0.245 0.045 0.048
Other 3 0.295 0.295 0.169 0.186
p < 0.05
Continuous 22 0.403 0.406 0.420 0.396
Proportion 11 0.234 0.258 0.285 0.312
Time to event 1 0.212 0.212 0.273 0.273
Count 1 0.114 0.114 0.070 0.070
Other 0
p > 0.05
Continuous 27 0.352 0.347 0.156 0.156
Proportion 30 0.220 0.192 0.052 0.027
Time to event 9 0.300 0.316 0.133 0.051
Count 3 0.296 0.377 0.036 0.035
Other 3 0.295 0.295 0.169 0.186
Fig. 3 The standardised target effect size by clinical area and primary end-point
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with 90% power and 5% significance (two-sided test),
using a sample size estimate for a chi-squared test
comparing two independent proportions (applying a
normal approximation correction for continuity) in
Stata version 9.
The target sample size was inflated to 2000 participants
(i.e. 1000 in each group) to allow for uncertainty about
non-adherence and the estimated proportions of
participants experiencing the primary outcome. We
regarded these parameter estimates as uncertain because
(1) they were estimated from observational data, (2) they
were based on the red blood cell transfusion rate only in
Bristol, (3) they were based on routinely collected data,
using definitions for elements of the composite primary
outcome which are not identical to those proposed for
the trial and (4) they were based on any compared with
no red blood cell transfusion, rather than on the number
of units of red blood cells likely to be transfused in
participants who breach the liberal threshold. No
adjustment was made for withdrawals or loss to follow-
up, as both rates were expected to be very low.
We expected approximately two thirds of participants
to breach the haemoglobin threshold for eligibility.
Therefore, we predicted that we needed to register
approximately 3000 participants into the study as a
whole to allow 2000 participants to be randomised
into the main study.
The main outcome measure for the economic evaluation
was quality-adjusted life years (QALYs), which are de-
rived from EQ-5D-3L utilities measured on a continuous
scale and time under observation. The analysis of QALYs
required baseline utility to be modelled as a covariate;
the correlation between baseline and 3-month EQ-5D-
3L utilities was assumed to be ≥ 0.3 With a total sample
size of 2000, the trial had more than 95% power to detect
a standardised difference in continuous outcomes
between groups of 0.2 with 1% significance (two-sided
test). This magnitude of difference is conventionally con-
sidered to be ‘small’.
Following personal correspondence with the chief investi-
gator (B Reeves), it was clarified that the process was done
prospectively. The team spent a lot of time when designing
the trial before reaching the decision to consent the pa-
tients before the surgery and randomise after surgery; this
decision facilitated recruitment but made randomisation
24/7 challenging to implement and resulted in over 40% of
Fig. 4 The standardised observed effect size by clinical area and primary end-point
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consented patients being ineligible for randomisation (i.e.
did not breach the liberal threshold). Professor Reeves
highlighted how from his experience, ‘target difference’ is an
alien concept to many clinicians which results in him regu-
larly reverting to a ‘bracketing’ method, which is a standard
method in psychophysics for estimating a threshold, to
hone in on a target threshold difference which a clinician
believes to be important. This discussion highlights the im-
portance of communication within a study team and the
challenges regularly encountered when trying to elicit a tar-
get effect size for a sample size calculation.
CADET trial
One trial which reported using a pilot study to aid the
elicitation of the target effect size was by Richards et al.
[25], the CADET trial (ISRCTN32829227). This study was
a cluster trial; therefore, it was excluded from the full study.
However, initially cluster trials were being included since
they are an extension of individual RCTs so data extraction
was completed on this report. The trial was investigating
the effectiveness of collaborative care for depression in pri-
mary care.
We powered the trial at 90% (alpha = 0.05) to detect an
effect size of 0.4, which we regarded as a clinically
meaningful difference between interventions. This figure
was within the 95% confidence interval (CI) of the effect
predicted from data collected during our pilot work
(effect size 0.63, 95% CI 0.18 to 1.07). To detect this
difference would have required 132 participants per
group in a two-armed participant-randomised trial.
For our cluster trial, with 12 participants per primary
care cluster and an intra-cluster correlation (ICC) of 0.06
from our pilot trial, the design effect was 1.65 leading to
a sample size of 440. To follow up 440 participants, we
aimed to randomised 550 participants (anticipating 20%
attrition).
The trial observed an effect size of 0.26 but reached stat-
istical significance (p = 0.009). The ‘Discussion’ section in
the paper details that whilst the observed effect size was
less than the one which the study was powered on the
95% CI around the observed effect size included the tar-
get effect size. It also discussed that the observed effect
size was also within the CI of the smallest meaningful
difference in a recent meta-analysis.
After further discussion with the trial statistician, it
was clarified that the trial was designed based on a clin-
ically meaningful effect size of 0.4, which was independ-
ently identified. This was shown in the trial protocol
[26], which referenced two trials, a review and a clinical
Table 6 Standardised target and observed effect sizes by clinical area
Frequency Standardised target effect size Standardised observed effect size
Count Median Median
Clinical area
Cardiovascular 11 0.171 0.050
Critical care 2 0.151 0.016
Dermatology 9 0.368 0.061
Diabetes 3 0.316 0.166
Gastrointestinal 9 0.295 0.343
Geriatrics 2 0.290 0.331
Immunology 2 0.509 0.432
Lifestyle 5 0.300 0.065
Mental Health 18 0.332 0.165
Neurology 4 0.270 0.056
Obstetrics and Gynaecology 2 0.252 0.341
Oncology 4 0.255 0.143
Orthopaedics 6 0.331 0.164
Other 3 0.180 0.041
Paediatrics 9 0.362 0.230
Renal/Urology 6 0.296 0.019
Respiratory 7 0.229 0.009
Stroke 5 0.285 0.133
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opinion to estimate the target effect size. The pilot study
was used to demonstrate that a UK version of collabora-
tive care might be likely to achieve such an effect, in line
with collaborative care interventions in other countries
such as the USA.
This use of multiple methods to estimate the target ef-
fect size shows how thorough review of previous work
as well as an understanding of each of the methods can
benefit the estimation of the target difference.
Discussion
The study in this paper gives an indication of the most
commonly reported methods for target difference elicit-
ation as well as the use of multiple methods. This study
demonstrates what trialists’ are reporting and the jour-
ney they take to establish the target effect size.
We found that the most commonly used method was
the review of evidence method, so using previously pub-
lished research to aid the quantification of the antici-
pated effect size. This method was also used in tandem
with other methods, resulting in an overall percentage of
use of 52.3%.
The average standardised target effect sizes in the tri-
als was 0.300, which corresponds to a small effect. Only
five studies had a target effect size greater than 0.600.
The average observed effect size was 0.112, with the lar-
gest observed effect being 1.200 and only two studies
observing effect sizes greater than 0.600. These results
should be used when reviewing grant applications and
trials to determine if the target difference specified is
realistic.
The difference between the observed and anticipated
effect sizes is as expected since half of all studies are not
statistically significant [27]. In this study, 67.3% of stud-
ies gave a non-significant result. The observed effect was
larger than the target effect size in 19.6% of trials. A
relatively high proportion of published HTA-funded
studies are meeting their target effect size, though the
effect sizes were small in all clinical areas.
Based on the case studies, it is clear that transparency
is required when discussing an estimated target effect
size. It could be that some trialists do not want to report
that they used multiple methods, whereas the use of
multiple methods of elicitation should result in a more
accurate estimate.
There were 19.6% of reports which did not discuss
where their target effect size came from. Since previous
research is used so frequently in target effect size elicit-
ation, and with other published research not stating
where the target effect size came from, this could result
in future trials using previous research which has no
founding or reason for the chosen effect size, which is a
cause for concern.
With the TITRe2 trial, the slight inflation of the sam-
ple size to account for the uncertainty of the observa-
tional data seems to be a sensible approach and is to be
recommended.
One limitation of this study is that the trials are all UK
based. However, this should not affect the generalisabil-
ity of the results. Even though only one journal was used
in this study, this particular journal captures high-quality
trials in the UK and thus the results are generalisable. A
potential implication of the high-quality of reporting is
that a larger amount of information is captured com-
pared to other journals. Whilst this could be deemed a
limitation of generalizability of results, these results
paint a clear picture of what is occurring currently in
clinical trials.
Conclusion
This study provides evidence that the median target
effect size is 0.300 in publicly funded-HTA trials in the
UK. It is recommended that there should be transpar-
ency in the quantification of the target effect size in
clinical trials and that the results in this paper on the
median effect sizes should be used to assess if a stated
effect size is realistic.
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